Literature DB >> 24705889

Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation.

Yiran Zhang1, Kaimin Hu, Yongxian Hu, Lizhen Liu, Binsheng Wang, He Huang.   

Abstract

The effect of bone marrow microenvironment on the cell cycle of acute lymphocytic leukemia (ALL) and the underlying mechanism has not been elucidated. In this study, we found that in normal condition, bone marrow mesenchymal stromal cells (BM-MSCs) had no significant effect on the cell cycle and apoptosis of ALL; in the condition when the cell cycle of ALL was blocked by genotoxic agents, BM-MSCs could increase the S-phase cell ratio and decrease the G2/M phase ratio of ALL. Besides, BM-MSCs could protect ALL cells from drug-induced apoptosis. Then, we proved that BM-MSCs affect the cell cycle arrest effect of genotoxic agents on ALL cells via p21 down-regulation. Moreover, our results indicated that activation of Wnt/β-catenin and Erk pathways might be involved in the BM-MSC-induced down-regulation of p21 in ALL cells. Targeting microenvironment-related signaling pathway may therefore be a potential novel approach for ALL therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24705889     DOI: 10.1007/s00277-014-2069-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Authors:  Courtney L Jones; Christy M Gearheart; Susan Fosmire; Cristina Delgado-Martin; Nikki A Evensen; Karen Bride; Angela J Waanders; Faye Pais; Jinhua Wang; Teena Bhatla; Danielle S Bitterman; Simone R de Rijk; Wallace Bourgeois; Smita Dandekar; Eugene Park; Tamara M Burleson; Pillai Pallavi Madhusoodhan; David T Teachey; Elizabeth A Raetz; Michelle L Hermiston; Markus Müschen; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Michael J Garabedian; Christopher C Porter; William L Carroll
Journal:  Blood       Date:  2015-08-31       Impact factor: 22.113

2.  ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment.

Authors:  Martina Chiu; Giuseppe Taurino; Erica Dander; Donatella Bardelli; Alessandra Fallati; Roberta Andreoli; Massimiliano G Bianchi; Cecilia Carubbi; Giulia Pozzi; Laura Galuppo; Prisco Mirandola; Carmelo Rizzari; Saverio Tardito; Andrea Biondi; Giovanna D'Amico; Ovidio Bussolati
Journal:  Blood Adv       Date:  2021-12-14

3.  Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-κB activation.

Authors:  Xiao-Bing Wu; Yang Liu; Gui-Hua Wang; Xiao Xu; Yang Cai; Hong-Yi Wang; Yan-Qi Li; Hong-Fang Meng; Fu Dai; Ji-De Jin
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

Review 4.  Human-derived normal mesenchymal stem/stromal cells in anticancer therapies.

Authors:  Cheng Zhang; Shi-Jie Yang; Qin Wen; Jiang F Zhong; Xue-Lian Chen; Andres Stucky; Michael F Press; Xi Zhang
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

Review 5.  The mechanisms of mutual relationship between malignant hematologic cells and mesenchymal stem cells: Does it contradict the nursing role of mesenchymal stem cells?

Authors:  Alireza Goodarzi; Mohsen Valikhani; Fatemeh Amiri; Armita Safari
Journal:  Cell Commun Signal       Date:  2022-03-02       Impact factor: 5.712

Review 6.  Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges.

Authors:  Myoung Woo Lee; Somi Ryu; Dae Seong Kim; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Keon Hee Yoo
Journal:  Leukemia       Date:  2019-01-31       Impact factor: 11.528

Review 7.  Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment.

Authors:  Yongsheng Ruan; Hye Na Kim; Heather Ogana; Yong-Mi Kim
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.